Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Acevedo Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,862,177

269 payments

Through program year 2025, Acevedo Clinical Research is reported as receiving $1,862,177 in research payments, across 269 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $25,918 3
2024 Research $114,239 14
2023 Research $457,456 34
2022 Research $357,390 19
2021 Research $105,252 33
2020 Research $339,413 77
2019 Research $462,509 89

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $1,799,957 204 payments
  2. Pfizer Inc. $39,432 54 payments
  3. Shire North American Group Inc $15,299 8 payments
  4. GlaxoSmithKline, LLC. $7,489 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $408,418 45 payments
  2. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $308,614 15 payments
  3. A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis $303,413 25 payments
  4. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $280,459 23 payments
  5. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $264,982 19 payments
  6. An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis $134,040 70 payments
  7. A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis $60,110 2 payments
  8. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $23,947 2 payments
  9. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $20,353 16 payments
  10. A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease $14,005 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record